Cangrelor to Clopidogrel or Prasugrel Transition Study

Inclusion Criteria

• Greater than or equal to 18 and less than 75 years of age, of either sex, and of any race.
• Stable CAD defined by the following criteria:
• Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic Q-waves on at least 2 contiguous electrocardiogram (ECG) leads.

or

• Previous revascularization by percutaneous coronary intervention or coronary artery bypass graft, and
• Treatment with aspirin 81 mg daily.

Exclusion Criteria

• Known intolerance or contraindication to cangrelor or prasugrel, or any ingredients of the respective formulation.
• Any antiplatelet (other than aspirin) or anticoagulant medication within the previous 30 days.
• Acute coronary syndrome within the previous 12 months.
• History of bleeding diathesis or known coagulopathy such as; impaired hemostasis; known international normalized ratio (INR) >1.5; past or present bleeding disorder (including congenital bleeding disorders, such as, von Willebrand's disease or hemophilia), acquired bleeding disorders, and unexplained clinically significant bleeding disorders; thrombocytopenia (platelet count less than 100,000/microliter [µL]), or history of thrombocytopenia or neutropenia associated with clopidogrel.
• Anemia (for example, hematocrit less than 35%).
• Prior stroke (any type), prior cerebral arteriovenous malformation or intracranial aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery).
• Known or suspected pregnancy, or lactating females.
• Known severe renal insufficiency (glomerular filtration rate less than 30 milliliter [mL]/min).
• Inability to provide informed consent.
• Moderate or severe hepatic impairment as per Investigator's discretion (elevation of liver function tests).
• Inability to swallow oral medication at time of randomization.
• Any clinically significant disease or condition affecting a major organ system, including but not limited to gastrointestinal, renal, hepatic, endocrinologic, broncho-pulmonary, neurological, or metabolic disease.
• Any surgical or medical condition which, in the judgment of the Investigator, might interfere with the pharmacokinetics, distribution, metabolism, or excretion of the study drug (if applicable).
• Treatment with other investigational medicinal products or devices within 30 days or 5 half-lives, whichever is longer, prior to the administration of the drug, or planned use of investigational medicinal products or devices.
• Participants who, for any reason, are deemed by the Investigator to be inappropriate for this study, including participants who are unable to communicate or to cooperate with the Investigator.
• Participant is the Investigator or his/her deputy, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.
• Active pathological bleeding, or a history of transient ischemic attack.